Metagenomi Therapeutics, Inc.
MGX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001785279
In the last 90 days, Metagenomi Therapeutics, Inc. insiders filed 1 open-market purchase and 3 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $7.45M in total; no superinvestor holds it.
Holders of 5% or more of MGX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Metagenomi Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Metagenomi Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Metagenomi Therapeutics, Inc., newest first.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 20264:05 PM ET | Thomas Brian C. | 13G | 7.30%2.76M shares | New | Jun 30, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Metagenomi Therapeutics, Inc. shares.
No Form 144 notices for Metagenomi Therapeutics, Inc. are on file.